CELLMED Research GmbH, founded in 2006, is an Austrian Life Science Company focused on research and development of cellular therapies, in particular on the manufacturing and clinical application of cellular immunotherapy for the treatment of solid tumors. A clinical study in phase I on the safety of PROCURE® for the treatment of ovarian cancer is currently under way. PROCURE® is composed of autologous, double loaded dendritic cells that are patented in Europe. Corresponding patents in USA and Japan have been filed.
In addition to CELLMED as the parent enterprise the company consists of two fully owned subsidiaries: LIFE RESEARCH Technologies GmbH (responsible for clinical research on cellular immunotherapy for the treatment of cancer) and Cellpro Danube GmbH (responsible for the manufacturing and control of clinical test material). To fulfill the high quality standards for cellular therapy Cellpro Danube has built a new, modern, officially authorized cleanroom production facility in compliance with the stringent international GMP (GMP = Good Manufacturing Practice) guidelines.
With financial support from national funding institutions CELLMED’s - mostly private - owners have invested in the further development of the company. Future financing is secured through operating profits, through atypical silent partnerships in the subsidiary companies. New investors are welcome to inform themselves at anytime about current investment possibilities in new development projects within the dynamic field of cancer research and the establishment of this innovative therapy within the growing market of cancer treatments.
LIFE RESEARCH Technologies GmbH is a highly innovative Life Science Company based in Vienna. Its main research focus is on the development of a unique personalized immunotherapy for the treatment of ovarian cancer.
This immunotherapy fights cancer by stimulation and activation of the body’s own immune response thus establishing a basis for delaying or even preventing a relapse.
The best time for treatment with cellular therapy is after surgical removal of the primary tumour and after chemo- or radiation therapy respectively.
With PROCURE® LIFE RESEARCH has the vision of being able to provide a treatment option for cancer patients offering high quality of life with minimal side effects.
Cellpro Danube GmbH is a Contract Manufacturing Organization (CMO) that offers the manufacturing and control of products in the field of “Advanced Therapies” (EU Regulation 1394/2007).
The development of such products necessitates a modern certified cleanroom production facility to guaranty that all processing steps take place in a sterile, aseptic environment. Cellpro Danube GmbH has a production area of 415 square meters with cleanroom areas of the categories D, C, B and A in compliance with international regulations for sterile products. The facility is located within the Regional Innovation Center (RIZ) in Krems an der Donau in Lower Austria. It has been examined and certified for the production of clinical trial drugs for the phases I - III by AGES, the Austrian Agency for Health and Food Security.
Insights into the production: